Ajanta Pharma is currently trading at Rs. 3075.00, up by 62.85 points or 2.09% from its previous closing of Rs. 3012.15 on the BSE.
The scrip opened at Rs. 3057.70 and has touched a high and low of Rs. 3087.00 and Rs. 2981.00 respectively. So far 6316 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3314.80 on 19-May-2026 and a 52 week low of Rs. 2335.00 on 30-Sep-2025.
Last one week high and low of the scrip stood at Rs. 3,314.80 and Rs. 2850.60 respectively. The current market cap of the company is Rs. 38357.74 crore.
The promoters holding in the company stood at 66.25%, while Institutions and Non-Institutions held 26.64% and 7.12% respectively.
Ajanta Pharma’s promoter entity -- Ravi Agrawal Trust has sold 34.50 lakh equity shares, representing 2.76% of total shareholding, of the company through an open market transaction worth Rs 1023.96 crore. The shares were disposed at an average price of Rs 2,968 apiece.
Meanwhile, Kotak Mahindra Mutual Fund has bought around 21.02 lakh equity shares of the company through an open market transaction worth Rs 623.96 crore. The shares have been acquired at an average price of Rs 2,968 apiece.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1787.10 |
| Dr. Reddys Lab | 1271.75 |
| Cipla | 1376.25 |
| Zydus Lifesciences | 1097.90 |
| Lupin | 2248.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: